Elite Growth website background copy.jpg

The New Standard In Specials Medicine

MGC Pharmaceuticals

MGC Pharmaceuticals Limited (LSE: MXC) is a biopharma company with a “Nature to Medicine” strategy at the forefront of the emerging phytocannabinoid and plant derived medicine markets. The company’s mission is to build an innovative, global bio-pharma company providing standardised, affordable plant derived medicines of the highest regulatory compliance for targeted global markets. 

 

MGC Pharma’s goal is to facilitate the transformation of Phytocannabinoids into true medicinal product pipelines, and to provide breakthrough solutions for prevalent global health issues to improve the quality of patients’ lives and contribute to improved public health.  

 

MGC believes that Phytomedicine will effectively treat previously unmet medical needs and improve the lives of patients, and MGC embraces this by creating Phytocannabinoid-based medicine products through developing the Company’s own proprietary medical cannabis formula via clinical trials in Europe, Israel, and Australia.

 

As such MGC currently holds pipelines for Phytomedicines, both proprietary and for third parties, all under GMP certified regulations and facilities. MGC has developed an efficient production pipeline of phytocannabinoid derived medications, with multiple products currently being prescribed to patients, and products in clinical development and testing. 

 

MGC will be developing clinical pathways for several products in the UK market, and has chosen Elite Pharmaco as its distribution and business development partner, and together we aim to establish product efficacy and acceptance for its phytomedicines product which will provide many patients with the NHS prescribed and covered products they need.

MGC Pharma.png
 

Grovida

 

GroVida aspires to become a world leader in the production of the highest quality medical cannabis by delivering cutting edge solutions to evolving patient needs.”

GroVida has 20,000m2 of high technology greenhouse operational in the South of Portugal. Alongside this our European Cannabis Hub offers a complete range of services from drying to manufactured final dosage forms.

GroVida has created a European Cannabis Hub, with facilities in place for the cultivation, processing, manufacturing and logistics of cannabis-based preparations. They can supply API´s and finished products tailored to our client’s specific needs. In conjunction with Elite Pharmaco, their European Cannabis Hub offer logistics, product development and market access to licensed producers and brands worldwide.

Grovida.png
Little Green Pharma.png

Little Green Pharma

Little Green Pharma is a responsive organisation with a proven ability to quickly adapt and succeed in a dynamic, fast-moving medicinal cannabis market environment. It was the first medical cannabis company in Australia to produce locally-grown medical-grade cannabis products, and has manufactured Australian medical grade cannabis products since August 2018.

 

Their vision is to transform the lives of patients globally, and for LGP patients’ needs are a priority, and drive their focus on providing a range of accessible, natural therapeutic solutions to patients in Australia and overseas. They work closely with medical practitioners to assist them with applications for medical cannabis products, saving patients time and money.

Australia has some of the strictest cannabis growing and manufacturing regulations in the world imposed by key regulators, including the Office of Drug Control (ODC) and the Therapeutic Goods Administration (TGA). Their medicinal cannabis products are manufactured in accordance with Good Manufacturing Practices (GMP) requirements and tested to stringent Australian quality standards, and as such they have an exclusive agreement for manufacturing services at a TGA GMP-certified manufacturing facility.

Little Green Pharma intends to progress a number of clinical programmes and explore alternative drug delivery technologies with a view to supplying any resulting products through the SAS-B approval pathway and potentially through the drug registration pathway. The company intends to: 

  • progress research and development of its liposomal small particle technology and patented formulation; 

  • explore new formulations that utilise the ARISE technology; and 

  • continue to undertake research and development of alternative delivery techniques with the aim of identifying additional patentable innovations

 
 

Cannim

Cannim operates farms in Jamaica and Australia, has established a network of EU GMP manufacturers and alliances, delivering a range of branded products to bring relief in many forms to people across the world.

Cannim continues to create scale in its operations, giving us the ability to meet the needs of the ever-growing body of medicinal cannabis users. We are pioneering the development of the category, creating new ways for patients to effectively absorb our product, leading research into the effects of cannabis on a variety of conditions, pioneering its usefulness for others, and ensuring those in need get what they need when they need it at a price that’s fair.

Elite Pharmaco works with Cannim to bring a range of manufactured products to market in the UK and Europe.

Cannim.png